<?xml version='1.0' encoding='utf-8'?>
<document id="28283499"><sentence text="Metabolite Identification, Reaction Phenotyping, and Retrospective Drug-Drug Interaction Predictions of 17-Deacetylnorgestimate, the Active Component of the Oral Contraceptive Norgestimate."><entity charOffset="104-127" id="DDI-PubMed.28283499.s1.e0" text="17-Deacetylnorgestimate" /><entity charOffset="176-188" id="DDI-PubMed.28283499.s1.e1" text="Norgestimate" /><pair ddi="false" e1="DDI-PubMed.28283499.s1.e0" e2="DDI-PubMed.28283499.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28283499.s1.e0" e2="DDI-PubMed.28283499.s1.e1" /></sentence><sentence text="Ortho Tri-Cyclen, a two-drug cocktail comprised of ethinylestradiol and norgestimate (13-ethyl-17-acetoxy-18, 19-dinor-17α-pregn-4-en-20yn-3 oxime), is commonly prescribed to avert unwanted pregnancies in women of reproductive age"><entity charOffset="51-67" id="DDI-PubMed.28283499.s2.e0" text="ethinylestradiol" /><entity charOffset="72-84" id="DDI-PubMed.28283499.s2.e1" text="norgestimate" /><entity charOffset="86-146" id="DDI-PubMed.28283499.s2.e2" text="13-ethyl-17-acetoxy-18, 19-dinor-17α-pregn-4-en-20yn-3 oxime" /><pair ddi="false" e1="DDI-PubMed.28283499.s2.e0" e2="DDI-PubMed.28283499.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28283499.s2.e0" e2="DDI-PubMed.28283499.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28283499.s2.e0" e2="DDI-PubMed.28283499.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28283499.s2.e1" e2="DDI-PubMed.28283499.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28283499.s2.e1" e2="DDI-PubMed.28283499.s2.e2" /></sentence><sentence text=" In vivo, norgestimate undergoes extensive and rapid deacetylation to produce 17-deacetylnorgestimate (NGMN), an active circulating metabolite that likely contributes significantly to norgestimate efficacy"><entity charOffset="10-22" id="DDI-PubMed.28283499.s3.e0" text="norgestimate" /><entity charOffset="78-101" id="DDI-PubMed.28283499.s3.e1" text="17-deacetylnorgestimate" /><entity charOffset="103-107" id="DDI-PubMed.28283499.s3.e2" text="NGMN" /><pair ddi="false" e1="DDI-PubMed.28283499.s3.e0" e2="DDI-PubMed.28283499.s3.e0" /><pair ddi="false" e1="DDI-PubMed.28283499.s3.e0" e2="DDI-PubMed.28283499.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28283499.s3.e0" e2="DDI-PubMed.28283499.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28283499.s3.e1" e2="DDI-PubMed.28283499.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28283499.s3.e1" e2="DDI-PubMed.28283499.s3.e2" /></sentence><sentence text=" Despite being of primary significance, the metabolism and reaction phenotyping of NGMN have not been previously reported"><entity charOffset="83-86" id="DDI-PubMed.28283499.s4.e0" text="NGMN" /></sentence><sentence text=" Hence, detailed biotransformation and reaction phenotyping studies of NGMN with recombinant cytochrome P450 (P450), recombinant uridine 5'-diphospho-glucuronosyltransferases, and human liver microsomes in the presence and absence of selective P450 inhibitors were conducted"><entity charOffset="71-74" id="DDI-PubMed.28283499.s5.e0" text="NGMN" /></sentence><sentence text=" It was found that CYP3A4 plays a key role in NGMN metabolism with a fraction metabolized (fm) of 0"><entity charOffset="46-49" id="DDI-PubMed.28283499.s6.e0" text="NGMN" /></sentence><sentence text="57" /><sentence text=" CYP2B6 and to an even lesser extent CYP2C9 were also observed to catalyze NGMN metabolism"><entity charOffset="75-78" id="DDI-PubMed.28283499.s8.e0" text="NGMN" /></sentence><sentence text=" Using this CYP3A4 fm value, the predicted plasma concentration versus time area under the curve (AUC) change in NGMN using a basic/mechanistic static model was found to be within 1"><entity charOffset="113-116" id="DDI-PubMed.28283499.s9.e0" text="NGMN" /></sentence><sentence text="3-fold of the reported NGMN AUC changes for four modulators of CYP3A4"><entity charOffset="23-26" id="DDI-PubMed.28283499.s10.e0" text="NGMN" /></sentence><sentence text=" In addition to NGMN, we have also elucidated the biotransformation of norgestrel (NG), a downstream norgestimate and NGMN metabolite, and found that CYP3A4 and UGT1A1 have a major contribution to the elimination of NG with a combined fm value of 1"><entity charOffset="71-81" id="DDI-PubMed.28283499.s11.e0" text="norgestrel" /><entity charOffset="83-85" id="DDI-PubMed.28283499.s11.e1" text="NG" /><entity charOffset="16-17" id="DDI-PubMed.28283499.s11.e2" text="NGMN" /><entity charOffset="118-119" id="DDI-PubMed.28283499.s11.e3" text="NGMN" /><entity charOffset="216-217" id="DDI-PubMed.28283499.s11.e4" text="NG" /><pair ddi="false" e1="DDI-PubMed.28283499.s11.e2" e2="DDI-PubMed.28283499.s11.e2" /><pair ddi="false" e1="DDI-PubMed.28283499.s11.e2" e2="DDI-PubMed.28283499.s11.e0" /><pair ddi="false" e1="DDI-PubMed.28283499.s11.e2" e2="DDI-PubMed.28283499.s11.e1" /><pair ddi="false" e1="DDI-PubMed.28283499.s11.e2" e2="DDI-PubMed.28283499.s11.e3" /><pair ddi="false" e1="DDI-PubMed.28283499.s11.e2" e2="DDI-PubMed.28283499.s11.e4" /><pair ddi="false" e1="DDI-PubMed.28283499.s11.e0" e2="DDI-PubMed.28283499.s11.e0" /><pair ddi="false" e1="DDI-PubMed.28283499.s11.e0" e2="DDI-PubMed.28283499.s11.e1" /><pair ddi="false" e1="DDI-PubMed.28283499.s11.e0" e2="DDI-PubMed.28283499.s11.e3" /><pair ddi="false" e1="DDI-PubMed.28283499.s11.e0" e2="DDI-PubMed.28283499.s11.e4" /><pair ddi="false" e1="DDI-PubMed.28283499.s11.e1" e2="DDI-PubMed.28283499.s11.e1" /><pair ddi="false" e1="DDI-PubMed.28283499.s11.e1" e2="DDI-PubMed.28283499.s11.e3" /><pair ddi="false" e1="DDI-PubMed.28283499.s11.e1" e2="DDI-PubMed.28283499.s11.e4" /><pair ddi="false" e1="DDI-PubMed.28283499.s11.e3" e2="DDI-PubMed.28283499.s11.e3" /><pair ddi="false" e1="DDI-PubMed.28283499.s11.e3" e2="DDI-PubMed.28283499.s11.e4" /></sentence><sentence text=" The data presented in this paper will lead to better understanding and management of NGMN-based drug-drug interactions when norgestimate is coadministered with CYP3A4 modulators"><entity charOffset="86-87" id="DDI-PubMed.28283499.s12.e0" text="NGMN" /></sentence><sentence text="" /></document>